Aim Brain-derived neurotrophic factor (BDNF ) is associated with antidepressant response on the cellular level, in animal models, and in clinical studies. A common variant in the BDNF gene results in a substitution of a methionine (Met) for a valine at the amino acid position 66. Previous studies reported that the Met variant results in enhanced response to antidepressant medications. These findings may be at odds with studies indicating that on a cellular level the Met variant impairs the secretion of BDNF.
Introduction
Brain-derived neurotrophic factor (BDNF) is a neurotrophic peptide that supports survival and neurite growth in neurons [1, 2] , and promotes synaptic connections during development [3] . Antidepressant medications increase BDNF in the brain [4, 5] . Moreover, delivering BDNF into the brain [6, 7] or even into the periphery [8] may result in antidepressant-like effects in animal models of depression. In humans, BDNF blood levels may predict antidepressant response [9] . BDNF also induces neurogenesis [10] , and is important in maintaining the viability of new neurons in the brain that arise after antidepressant treatment [11, 12] .
In animal models, the rs6265 Met variant impairs memory function after stress testing [23] .
BDNF binds to the neurotrophic tyrosine kinase receptor 2 (NTRK2; also called TrkB) on neurons, leading to the phosphorylation of the nuclear transcription factor cyclic AMP responsive element binding protein 1 (CREB1). Phosphorylation of CREB1 results in the synthesis of a variety of proteins that are important in neuronal function. In animal models, expression of CREB1 results in behavioral changes reminiscent of antidepressants [28] . CREB binding protein (CREBBP; also known as CBP) is a coactivating transcriptional factor essential for CREB function. CREBBP in animal models leads to increased transcription of BDNF by neurons [29] . The NTRK2, CREB1, and CREBBP genes contain numerous polymorphisms, which have been associated with depression or antidepressant response in some studies [30] [31] [32] .
We used a recently developed principal component (PC) method for testing total gene effects on clinical outcomes in depressed geriatric patients treated with paroxetine or mirtazapine of multiple BDNF, NTRK2, CREB1, and CREBBP polymorphisms chosen to provide a wide coverage of genetic variation at these loci. Rather than focusing on BDNF alone, we targeted the broader pathway because previous results have suggested an interaction among the factors in increasing risk for geriatric depression [31] . We hypothesized that polymorphisms at multiple loci in this important signaling pathway might affect antidepressant response. We studied a geriatric sample because little is known about predictors of antidepressant response in elders. Our results indicate that BDNF genetic variation affects response to paroxetine but not mirtazapine among elderly patients. There was also an interaction between BDNF and CREB1 in predicting treatment outcomes for paroxetine. None of the genes investigated had any effect on change in cognition.
Materials and methods
As described in previous publications [33, 34] , our study group included 246 outpatients from 18 clinics in the USA with major depressive disorder who were treated with either paroxetine or mirtazapine [paroxetine (N = 124); mirtazapine (N = 122)] in an 8-week, double -blind, randomized trial. All patients provided an informed consent, and IRB approval was obtained at each site. All patients were aged 65 years or older and free of major medical problems for at least 3 months. Twenty patients reported a minority ethnic background and the rest were of self-reported European Caucasian ancestry. When screened initially for the study, all met the DSM-IV criteria for major depression (single or recurrent), had Mini Mental State Examination [35] scores above the 25th percentile for their age, and had a Hamilton Depression Rating Scale 17-item (HDRS-17) [36] score of at least 18. Methods for patient recruitment and screening as well as complete demographic details on the study sample have been described previously [33, 34] .
Because depression can result in cognitive deficits in older patients, and these deficits may improve with treatment, we also performed neuropsychological testing on all patients at baseline and at the end of the study period for those who completed the entire 8-week course of treatment. The following tests were performed: ListLearning task, Benton Visual Retention test, Trail Making test (parts A and B), Finger Tapping test, and Stroop Color and Word test. These tests assess delayed recall, visual perception, visual memory, visuoconstructional abilities, executive function, motor speed, and ability to shift perceptual set to process complex input.
Initially patients were treated with 15 mg mirtazapine (one active capsule and one placebo capsule) or 20 mg of paroxetine (two 10 mg capsules), given each evening. Increases in dose were allowed based on Clinical Global Impression change scores as described [33, 34] . Mood was rated using the HDRS-21.
Genetic markers were selected on the basis of the standard criteria [37] including demonstrated (based on the literature) or predicted (based on bioinformatic analysis) effects on protein abundance or function; association with depression or antidepressant response; location in regions such as exons, 3 0 UTR, intron boundaries, or one of the many regulatory elements involved in gene expression. We also selected SNPs that predicted other polymorphisms in the gene because of high linkage disequilibrium (LD), such that the tagging SNP complemented other selected markers to provide good coverage of the gene. For each tagging SNP, a 'bin' containing all SNPs in high LD was identified. High LD was defined as a pairwise r 2 of greater than 0.8. Prediction of LD bins and the selection of tagging SNPs was carried out using Haploview (Broad Institute, Cambridge, Massachusetts, USA) and the unrelated individuals from the HapMap CEU (60 individuals of European descent collected in Utah) [38] , which was the closest match to our study sample. 'Tagging' SNPs selected using the CEPH cohort retained a reasonable level of effectiveness across multiple non-African populations [39] . However, in some cases HapMap either did not contain a particular gene or genomic region, or a particular marker of interest was not present within the HapMap CEU cohort. In these cases, we utilized other SNP databases such as dbSNP. In general, only SNPs with a minor allele frequency of 5% or greater were considered. and CREB1 SNPs. LD maps for BDNF and CREB1 are shown in Figs 1 and 2. Similar information for NTRK2 and CREBBP is given in Supplementary Tables 1 and 2 The selected SNPs were genotyped as part of a larger project using a custom-designed Illumina Golden Gate assay (Illumina, Hayward, California, USA). The full assay consisted of 1152 SNPs drawn from 118 genes. Genotyping was carried out using Illumina's standard protocol. Two samples of known genotype (HapMap CEU) were included on each of the Sentrix Universal Array Matrixes to test for fidelity across assays. In addition, 10 of the 246 samples were genotyped twice on different Sentrix Universal Array Matrices. To check genotype calls, a total of 20 HapMap samples with known genotypes were included. Genotype calling and quality control, including contamination control, was carried out using BeadStudio v3 (Illumina). The GenCall Score, which is produced using clustering efficiency and a data-to-model fit score, and visual inspection were used as additional assessments of call fidelity, along with the internal repeats and samples of known genotype.
A comparison across the genotype groups for demographic and clinical characteristics was carried out using w 2 -tests or analysis of variance. A complete comparison of demographic and clinical characteristics between drug treatment groups was presented previously [33] .
For analysis, we used a gene-based PC approach [40] , utilizing an additive allelic model. For each locus, genotypes for all SNPs were used to compute PCs with the SAS PRINCOMP procedure (SAS Institute Inc., Cary, North Carolina, USA). The resulting PCs, which are continuous variables combining information from multiple SNPs, were tested for association with clinical outcomes. The PC approach potentially increases power by (a) reducing the number of tests per gene, yielding a less stringent multiple testing correction and (b) aggregating signal across SNPs so that the proportion of trait variance explained by a PC may be greater than that explained by any one SNP. The PC approach exploits the idea that genetic variants across a gene are likely to modify the same biological pathway. An added advantage of the PC approach is that PCs can be used to test genegene (G Â G) interactions.
The PC approach can be more powerful than haplotype analyses for testing multiple SNPs within a gene [41] . In effect, each PC measures an individual's relative genetic proximity to each of two complementary archetypal haplotypes determined by the signs of the individual SNP factor loadings. An individual is assigned the highest possible PC value when he carries two copies of the first haplotype and the lowest possible value when he carries two copies of the complementary haplotype. Other genotype combinations receive intermediate values. To make effect sizes interpretable, PC values were standardized by subtracting the minimum and dividing by the range. Thus, the lowest observed value of a standardized PC is always zero and the highest value is always one. When significant G Â G interactions were identified using the product of two PCs, we performed a second G Â G analysis to obtain a simpler description of the effect of the interaction on antidepressant response. For that analysis, PCs for one gene (either BDNF or CREB1) were analyzed as continuous variables. At the same time, PCs for the remaining gene were analyzed as dichotomous variables, coded to indicate whether the PC value was less than or at least 0.5. The term 'major' and 'minor' refer to the bins containing more and fewer individuals, respectively.
The primary outcome measure was change in HDRS-21 score over time, defined as the difference between baseline score and score at the last visit, divided by the baseline score. Thirty individuals who left the study before day 7 were not included in the analysis. Thus, 216 participants were included in the primary analysis, 99 who were treated with paroxetine and 117 who were treated with mirtazapine. Ordinary least square regression models were used to examine the associations between the HDRS-21 change score and the first two or three PCs for each of the loci. For BDNF and CREB1, we used the first two PCs. For NTRK2 and CREBBP, we used three PCs. Sex and number of weeks of participation in the study were included in the model. For BDNF and CREB1, four tests were performed: PC1 and PC2 as predictors of HDRS-21 score, for both the full sample and for Caucasians only. Hence, the threshold for significance was set using the Bonferroni inequality at 0.05/4 = 0.0125. For NTRK2 and CREBBP, six tests were performed: PC1, PC2, and PC3 as predictors of HDRS-21 score, for both the full sample and for Caucasians only. Hence, the threshold for significance was set at 0.05/6 = 0.008. In follow-up analyses to identify G Â G interactions, PCs that showed significant main effects were entered into a single analysis that included G Â G interaction terms represented by the product of two PCs. Likelihood ratio tests were used to compare statistical models.
Comparison of baseline measures for the 216 patients who completed the study versus those who did not indicated no significant differences in age, sex, BMI, ethnicity, or baseline HDRS-21 score.
To analyze the cognitive measures, we calculated the difference between the baseline score and the score obtained at the end of the trial. PCs for each gene were used as predictors of change in cognitive scores in a regression model. Because the apolipoprotein E (APOE) E4 allele may predispose to early cognitive decline, and because we previously reported an effect of the E4 allele on treatment outcomes in this sample [42] , we also performed analyses of the effects of BDNF PCs on cognitive change during the trial with number of E4 alleles included in the model. For each cognitive measure, when two tests were performed (PC1 and PC2 as predictors for BDNF and CREB1), the significance level was set at 0.05/ 2 = 0.025. When three tests were performed (PC1, PC2, PC3 for NTRK2 and CREBBP), the significance level was set to 0.05/3 = 0.016.
Haplotype frequencies were calculated using the Haplotype Estimation software in JMP Genomics 5.0 (SAS Institute Inc.) under the H1 hypothesis, which assumes LD and uses a selected estimation method.
Results
Genetic variation at the BDNF locus strongly affected treatment outcomes among patients treated with paroxetine, but only weakly affected outcomes among those treated with mirtazapine. Among paroxetine-treated patients, BDNF PC1 predicted change in HDRS-21 score (P = 0.00006), but the BDNF PC2 did not. For mirtazapine, the BDNF PC1 had a weaker effect on HDRS-21 change (P = 0.04, did not survive Bonferroni correction), whereas PC2 had no effect. Sex did not show any significant effect on HDRS-21 change score for either medication. When we restricted the analysis to the 197 Caucasian individuals contained in the subsample (N =216), the results were essentially the same (P = 0.00007 for PC1, paroxetine).
The first two BDNF PCs accounted for 56% of the total genetic variation in the 13 original BDNF SNPs (Table 3) . Examination of the correlations between individual SNPs and BDNF PC1 (Fig. 1, PC1 loadings) , indicated that jointly rs988712, rs11030086, rs6265, and rs988748 contributed heavily to the prediction of HDRS-21 change score (absolute value of correlations between SNPs and PC1 > 0.75) (Fig. 1) . The LD map for BDNF shows that these four SNPs are in strong LD. Box plots of HDRS-21 scores for each of these four SNPs are shown in Fig. 3 for the 216 patients included in the change score analysis. For each SNP, paroxetine-treated carriers of minor alleles showed less improvement. Box plots showing change scores (n = 2) (n = 29) (n = 68) (n = 8) (n = 41) (n = 68) (n = 8) (n = 36) (n = 55) (n = 65) (n = 47) (n = 5) (n = 62) (n = 31) (n = 6) (n = 51) (n = 54) (n = 12) (n = 47) (n = 40) (n = 12) We applied haplotype estimation to the four most heavily weighted SNPs (Table 4) . Two complementary 'yin-yang' haplotypes together account for 80% of all haplotypes in the sample, with similar frequencies in the mirtazapine and paroxetine groups. A-T-A-G, which includes the variant A allele at rs6265, occurs only once in a non-Caucasian individual. However, the sample included very few minorities. The A-T-A-G haplotype was associated with worse paroxetine response than the C-A-G-C haplotype.
For NTRK2, none of the first three PCs showed significant associations with change in HRDS-21 score. The first three NTRK2 PCs accounted for 48.7% of the genetic variation present in the 20 original SNPs (Table 3) .
For CREB1, among paroxetine-treated patients, PC1 showed a trend toward predicting HDRS-21 change (P = 0.06), whereas the CREB1 PC2 showed a significant effect (P = 0.02). Among the Caucasian subsamples, the effects were somewhat stronger (for PC1, P = 0.05; for PC2, P = 0.004). The first two CREB1 PCs accounted for 55% of the genetic variation contained in the original nine SNPs (Table 3 ). The SNPs with the heaviest loading in the significant CREB1 PC2 were rs2551639, rs4234080, and rs2194430 (Fig. 2) . Box plots showed that the rs2551639 G allele, the rs4234088 C allele, and rs2194430 G allele resulted in a greater improvement in HDRS-21 scores with paroxetine treatment (Fig. 5) . Box plots for the 183 individuals who completed the entire study are shown in Supplementary Fig. 4 (http://links.lww.com/FPC/A589). The SNPs with the heaviest loading on PC1, which showed a trend toward significance, were rs2253206, rs7569963, and rs2551941. Box plots for CREB1 PC1 are shown in Supplementary Figs 5 and 6 (http://links.lww.com/FPC/A590, http://links.lww.com/FPC/A591). The CREB1 PCs had no effect on HRDS-21 change among mirtazapine-treated patients, except for a marginal effect (P = 0.03, does not meet Bonferroni criterion) for PC1 in the Caucasian subsample. CREBBP PCs had no effect on treatment outcomes for either medication.
To identify potential G Â G interactions, we conducted a follow-up regression analysis for effects on the HRDS-21 change score in paroxetine-treated patients, simultaneously, including three PCs: BDNF PC1, CREB1 PC1, and CREB1 PC2. G Â G interactions between BDNF and each of the CREB1 PCs were also included. Both BDNF-CREB1 interactions were individually significant at P values equal to 0.045 and 0.006, respectively. A series of likelihood ratio tests confirmed that the three-PC model improved prediction of the HRDS-21 change over simpler prediction models (Table 5 ).
In the estimated model, genetic variation in BDNF had a strong association with paroxetine response for some individuals and not others, depending on the specific pattern of genetic variation in CREB1. We refit the model using dichotomous variables for the CREB1 PCs as described above. Individuals were then placed in one of the two groups: those in the major or more frequent bin on both CREB1 PCs and those in the minor or less frequent bin on at least one CREB1 PC. BDNF PC1 was treated as a continuous variable. For those in the two major bins for CREB1 variation, the effect of BDNF PC1 on the change score was -0.79 [95% confidence interval (CI) = -1.03, -0.55, P < 0.001]. For those in one or two of the minor bins for CREB1 variation, the effect of BDNF PC1 on the change score was -0.23 (95% CI = -0.45, -0.01, P = 0.04), less than one-third the effect size in the first group. The BDNF PC effect corresponds to the difference between the observed sample extremes of BDNF PC1 variation, with the A-T-A-G haplotype at the end associated with poor response. We also refit the model using a dichotomous variable for BDNF PC1 and treating the two CREB1 PCs as continuous variables. The two CREB1 PC effects were then added together. For patients in the major bin for BDNF PC1, the total CREB1 effect on the change score was 0.57 (95% CI = 0.21, 0.94, P = 0.003). For patients in the minor bin for BDNF PC1, the total CREB1 effect on the change score was 0.33 (95% CI = -0.09, 0.76, P = 0.12). The CREB1 effect corresponds to the difference between the observed sample extremes of CREB1 variation on both PCs. Poor response is associated with the less typical pattern of genetic variation for BDNF PC1, but the more typical pattern for both CREB1 PCs (Table 4) . (n = 76) (n = 37) (n = 4) (n = 62) (n = 32) (n = 5) (n = 3) (n = 28) (n = 84) (n = 4) (n = 27) (n = 68) (n = 11) (n = 106) (n = 6) (n = 93) In contrast to strongly significant BDNF genetic effects on change in the HDRS-21 score, none of the BDNF PCs predicted change in cognitive scores between baseline and the end of the 8-week treatment period that survived Bonferroni correction. NTRK2 PC2 barely reached Bonferroni significance (P < 0.013) for Finger Tapping test with the dominant hand. None of the other PCs for NTRK2, and none of the CREB1 or CREBBP PCs predicted change in cognitive scores. Descriptive statistics for the six cognitive tests are shown in Supplementary Table 3 (http://links.lww.com/FPC/A594).
Among the 99 paroxetine-treated patients included in the cognitive analysis, there were 21 APOE E4 heterozygotes and four APOE E4 homozygotes. Among the 117 mirtazapine-treated patients, there were 27 E4 heterozygotes. There were no significant effects of BDNF PC1 or PC2 on the cognitive change scores for paroxetine or for mirtazapine when the number of APOE E4 alleles was included in the model.
There were no significant differences at the level of P-value less than 0.01 in the mean age, BMI, final daily dose, or medication compliance among the genotype groups for any SNP with the following exceptions: BDNF rs11030102 for age in mirtazapine-treated patients, NTRK2 rs1187363 for compliance in paroxetine-treated patients, and NTRK2 rs3654 for compliance in mirtazapine-treated patients.
Given the large number of tests performed across the 53 SNPs, these results are difficult to interpret.
Discussion
Our results indicate that BDNF and CREB1 genetic variants predict the efficacy of paroxetine treatment in patients with geriatric depression. A linear combination of 13 BDNF SNPs computed with PCs analysis was a strong predictor of change in HDRS-21 score for paroxetinetreated patients. A CREB1 PC also showed a significant effect on treatment outcomes among paroxetine-treated patients. Furthermore, a significant G Â G interaction was detected between BDNF and CREB1. None of the PCs for NTRK2 or CREBBP were significant predictors after Bonferroni correction. Change in cognition between the beginning and end of the treatment period was not significantly affected by variation in any of the genes that we investigated.
The nonsynonymous rs6265 SNP (Val66Met) was strongly correlated with the BDNF PC1 that predicted paroxetine response. Also loading heavily on PC1 were rs988748, an intronic SNP with no known function, and rs988712 and rs11030086, both of which are located downstream in the BDNFOS gene. BDNFOS antisense RNA represses BDNF by binding to its transcripts. The inhibition of BDNFOS not only upregulates BDNF mRNA by two-fold to seven-fold, it also alters chromatin marks at the BDNF locus, leads to increased protein levels, and induces neuronal outgrowth and differentiation [14] . All of the BDNF/BDNFOS SNPs are in moderate-to-high pairwise LD with each other. Although our sample had only a few rs6265 minor allele homozygotes, the minor allele frequencies for the other three SNPs that loaded heavily on PC1 were larger.
Previously, it has been reported that the BDNF rs6265 SNP can affect antidepressant treatment outcomes in depression. Several groups have reported that the G variant (Met allele) at rs6265 resulted in better outcomes in patients treated with antidepressants [21, 22, 43] . In contrast, others have found no effect of rs6265 on antidepressant outcomes [44] , or that carriers of the Met allele had worse outcomes [45] .
It is unclear why our results regarding the effects of the BDNF Met allele (and minor alleles of other SNPs in strong LD with rs6265) differ from those of other investigators. Alexopoulos et al. [21] studied geriatric patients treated with escitalopram for 12 weeks. Taylor et al. [22] found a small but significant effect of the rs6265 Met allele on remission rates at 6-month follow-up in geriatric patients treated with a variety of antidepressants. Perhaps methodological differences from our study affected the results. However, our finding showing Met allele carriers have impaired antidepressant response would appear to support previous findings that the Met allele results in decreased secretion of BDNF [25] , and that BDNF Met/Met knock-in mice show impaired response to selective serotonin reuptake inhibitor antidepressant medication [15, 23, 46] . There is substantial evidence that antidepressants increase the secretion of BDNF [47] , and the Met allele may impair this effect.
Two complementary BDNF haplotypes represent B80% of the haplotypes in our sample at the four SNPs most highly weighted in the BDNF PC1. The PC analysis identified and grouped together the four SNPs comprising these yinyang haplotypes, and associated them collectively with treatment response. Some authors have suggested that yin-yang haplotypes indicate distinct ancestral lineages maintained by selection or historically separated populations [48] . However, the yin-yang phenomenon has been shown to be common and to be possible in well-mixed populations under neutral evolution.
In contrast to strong effects detected for BDNF SNPs, NTRK2 variants were not predictors of antidepressant efficacy. Dong et al. [30] reported that the synonymous NTRK2 SNP rs2889657 was a predictor of desipramine or fluoxetine response among Mexican-Americans. The rs2889657 variant was infrequent in our cohort (minor allele frequency = 4%). In our PC analysis, rs2889657 was strongly correlated with NTRK2 PC2, but PC2 did not show a significant association with HDRS-21 change score. Individual statistical testing showed no significant effects of rs2889657 among either paroxetine-treated or mirtazapine-treated patients. Differences between our study and that of Dong et al. [30] in terms of ethnicity, methodology, and study drugs may account for these varying results.
The CREB1 SNP rs2551639 located in intron 1 was strongly correlated with CREB1 PC2, a predictor of response to paroxetine. Other SNPs in strong LD with rs2551639 are located in noncoding regions, except for the synonymous exon SNP rs2709416 and a nonsynonymous exon coding SNP rs2551949, both found in the adjacent gene FAM119A (METTL21A) that has no known function. The CREB1 SNP rs4234080 was also correlated with PC2. This SNP is located in the 5 0 -untranslated region FAM119A. There is little LD between rs2551639 and rs4234080, suggesting that the two contribute independently in predicting paroxetine outcomes. The intronic SNP rs2194430 also contributed to PC2 prediction of paroxetine outcomes, and is in LD with other HapMap SNPs that are all intronic except for rs2709376, which is in the putative CREB1 promoter, and rs2709417, which is in the FAM119A 3 0 UTR. It is possible that rs2551639, rs4234080, or rs2194430 are in LD with additional as yet unknown CREB1 SNPs with functional properties. The SNPs rs2253206, rs7569963, and rs2551941 contributed heavily to CREB1 PC1, which showed a trend toward predicting paroxetine response. The SNP rs2253206 is in the putative CREB1 promoter, whereas rs2551941 and rs7569963 are past the 3 0 end of CREB1.
Our CREB1 results may support those of other investigators. Juhasz et al. [32] reported that the CREB1
promoter SNP rs2253206 was associated with depression. In our sample, this SNP loaded heavily on CREB1 PC1. Dong et al. [30] found that the CREB1 intronic SNP rs3730276, which is in strong LD with rs2194430 that loaded heavily on PC2, was associated with depression. Perlis et al. [49] found that the CREB1 SNP rs7569963 was associated with suicidality in STAR*D men treated with citalopram. Serretti et al. [50] reported that rs7569963 predicted treatment resistance to a variety of antidepressants, including paroxetine or mirtazapine. The SNP rs11904814, which is in strong LD with rs7569963, may be associated with depression [51] . In our sample, rs7569963 contributed to CREB1 PC1.
We detected significant BDNF-CREB1 G Â G interactions. BDNF binding to the NTRK2 receptor results in phosphorylation of CREB1, which in turn alters gene expression. Antidepressant-induced BDNF effects have been shown to be dependent on intact CREB1 [52] . Furthermore, because BDNF and CREB1 proteins interact functionally, genetic variants at the BDNF and CREB1 loci might be expected to interact to modify antidepressant treatment outcomes.
We originally chose to study paroxetine and mirtazapine because of their contrasting mechanisms of action. BDNF and CREB1 effects were present only in the paroxetinetreated group. Previously, it was reported that BDNF polymorphisms had no effect on mirtazapine outcomes [53] , and our results support that finding. However, mirtazapine treatment increases hippocampal BDNF [54] . Perhaps some other cellular effect of mirtazapine obviates the effects of BDNF polymorphisms on treatment outcomes. Paroxetine and mirtazapine have different effects on the brain. Paroxetine primarily inhibits the serotonin reuptake transporter, and to a lesser degree at high doses, the norepinephrine reuptake transporter [55] . In contrast, mirtazapine blocks a2 adrenergic autoreceptors and heteroreceptors, thus increasing both adrenergic and serotonergic activity in the brain. Furthermore, mirtazapine blocks postsynaptic serotonin 2 and 3 class receptors, and the histamine H1 receptor [56] . Interactions of BDNF with other neurotransmitter systems are poorly understood, but the differing effects of BDNF polymorphisms could be because of the contrasting pharmacology of paroxetine and mirtazapine.
We did not find any CREBBP polymorphisms that predicted antidepressant outcomes. Wilkie et al. [57] tested the rs130003 CREBBP SNP, which is synonymous (Y651Y) on the protein level. As in our study, they found no significant effect of this SNP on response to a variety of antidepressants including paroxetine.
Because ethnic background may affect antidepressant response, we analyzed our clinical outcomes utilizing the full sample and also the subsample of 197 Caucasians.
Results were essentially the same. For some loci, effects were slightly stronger in the Caucasian subsample than in the full sample, suggesting that different genetic effects might be present in minorities. However, it is not possible to definitively test this hypothesis with our small heterogeneous minority sample.
We did not find that BDNF genetic variation affected change in cognition in elderly depressed patients between the beginning and the end of the trial. This seems surprising, given good evidence that the BDNF Met allele is associated with cognitive impairment [24, 27] . It may be that the BDNF Met allele affects cognition, but not antidepressant-induced change in cognition. The time course for improvement in cognition in the depressed elderly after antidepressant treatment is unknown. It is possible that a longer treatment period would be required to detect an effect. Furthermore, because our patients were screened for cognitive impairment before enrollment in the trial, there was actually little opportunity for cognitive improvement with antidepressant treatment.
Conclusion
We found robust evidence that BDNF polymorphisms affect antidepressant efficacy in patients treated with paroxetine, but not with mirtazapine. For the rs6265 Val/ Met variant, we found that carriers of the Met allele, and of minor alleles at other closely-linked SNPs, were less likely to respond to paroxetine than were Val homozygotes. A limitation of this study is that the number of minor allele carriers at these BDNF SNPs was relatively small. CREB1 SNPs also had an effect on paroxetine efficacy, although the magnitude of the effect was less than for BDNF. Furthermore, our PC approach successfully identified BDNF-CREB1 interactive effects, such that the strength of the BDNF association with response to paroxetine depended on genetic variation present in CREB1. We quantified change in a wide variety of cognitive measures over the course of the 8-week trial, but none of the genetic markers tested were strongly significant predictors. Our finding that the BDNF rs6265 Met variant and linked polymorphisms have a negative effect on antidepressant efficacy are at variance with some other reports, but consistent with cell biology and animal models suggesting this variant impairs function of the BDNF pathway. Additional studies will be required to resolve this issue, and to determine whether these results apply to younger patients.
